Welcome to the era of mindful medicine.
Psilera delivers therapies designed to change the way the world thinks.
The Latest From The Lab:
Psilera wins
$2 Million grant to advance AUD
treatments from the
National Institutes of Health
Read the full press release here!
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds. Several more patents expected by 1H 2024.
-
The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small molecule drug discovery is done, giving rise to more patient-centric therapy options for those suffering from neurological conditions.
Based on the current pipeline, our focus is on hard-to-treat disorders, many of which have no currently available treatments, such as Frontotemporal Dementia (FTD).
UPCOMING EVENTS
UPCOMING EVENTS
January 11 -13
March 10 - 11
Miami, FL
February 28 - 29
Boston, MA
San Francisco, CA
Neuroscience Innovation Forum & JPM
Chris Witowski, PhD, Co-Founder & CEO, will be speaking at the 9th Annual Neuroscience Innovation Forum. The “Meeting the Promise of Psychedelics Panel: Expected Trends for 2026” is set to offer critical insights into the year ahead for the neuroplastogen and psychedelic industries. He will be joined by Co-Founder and CSO Jackie von Salm, PhD to meet with development partners at the JP Morgan Healthcare Conference. To connect with our team while they are in California, please contact info@psilera.com to arrange a time.
LSX Investival Showcase USA
The Business Development team will be hitting the beautiful beaches of Miami for the LSX Investival Showcase. This will be the first year the USA will host this unique event where life-science innovators and game-changing capital and partnership opportunities unite. Co-Founder Chris Witowski, PhD, EVP of Corporate Dev. Scott Rairigh and Marketing Director Katie DeMarsh will be available to connect if you would like to learn more!
Neuroscience Innovation
Pharma Partnering Summit
In the spring, Jackie von Salm, PhD will be speaking at the Neuroscience Innovation Pharma Partnering Summit in Boston. Focused on accelerating collaboration and partnership across neurology and psychiatry, the Summit will allow key opinion leaders in the CNS space the opportunity to forge new connections. If you will be in Boston for the event and would like to connect, please message us at info@psilera.com.